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Abstract
Background: Aseptic loosening (AL) is the main problem of total joints replacement (TJR) by the
implantation of permanently prosthetic components. In vitro and in vivo studies have clearly
demonstrated that wear debris and its byproducts could trigger inflammation in the peri-implant
tissue. Lipoxins (LXs) are endogenous eicosanoids synthesized locally from arachidonate acid (AA)
at sites of inflammation and mediate pro-resolving activity. A number of studies have demonstrated
the effect of LXA4 to counteract inflammation in different cell and animal models, but till now, no
relative report about the role of LXs in progress or prevention of AL.
Methods: Murine RAW264.7 macrophage cell line and MC3T3-E1 osteoblasts (OB) cell line were
purchased. Co-cultured model of these two cell lines was established. To explore the effect of
exogenous Lipoxin A4 (LXA4) on polymethylmethacrylate (PMMA) induced inflammation, pro-
inflammatory cytokines including TNF-α, IL-1β, PGE2 and GM-CSF were measured by ELISA kits
and bone resorption was quantified by measuring calcium release from 5-day-old mice calvaria in
vitro. To determine further the endogenous effect of LXA4, cells were co-cultured and with or
without 15-lipoxygease (15-LO) blocking by 15-LO siRNA. Both real-time PCR and western
blotting were applied to confirm the inhibitory efficiency of 15-LO by siRNA.
Results: 0.1 mg/ml, 0.5 mg/ml and 1.0 mg/ml PMMA showed a time-dependent manner to trigger
production of all the pro-inflammatory cytokines studied. Exogenous 0–100 nM LXA4 presented an
inhibitory effect on both generation of above cytokines and PMMA stimulated calvarial bone
resorption with a dose-dependent manner. LXA4 in supernatant from neither rest macrophages
nor macrophages cultured alone exposing to PMMA was detectable. In co-cultured cells challenged
by PMMA, LXA4 was increased significantly, while, this enhance could be partly inhibited by 15-LO
siRNA. When LXA4  generation was blocked with 15-LO siRNA, the PMMA induced pro-
inflammatory cytokines were elevated and bone resorption was accelerated.
Conclusion: In the present study, we demonstrated that LXA4 had a favorable inhibitory effect on
PMMA-induced inflammation in a macrophage and OB co-culture system.
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Background
The total joints replacement (TJR) by the implantation of
permanently prosthetic components has been one of the
most successful clinical procedures in orthopaedic surgery
of recent decades[1]. However, despite the clinical effec-
tiveness of joint replacement arthroplasty, aseptic loosen-
ing (AL) of the prosthesis still remains a major problem,
especially for long-term success and survival of prosthe-
sis[2]. In most cases of AL, revision surgery is needed,
which will cause serious damage physically and mentally
to the sufferers[3]. Among all the reasons of AL, inflam-
matory reaction induced by excessive production of wear
particles from the implant components and consequent
peri-implant osteolysis are believed to be the primary
causes [4,5].
In vitro and in vivo studies have clearly demonstrated that
wear debris and its byproducts could trigger a series of cel-
lular biology responses[6]. Phagocytic cells engulfing par-
ticulate debris become activated, release pro-
inflammatory cytokines, degradative enzymes, reactive
oxygen radicals and other substances, stimulate osteo-
clasts to undermine the prosthetic bed [7-9]. Of the entire
cellular population in the foreign body and chronic
inflammation to wear particles, macrophages comprise
60–80% [10-13].
While most of the studies have been concentrated on
understanding excessive bone resorption in osteolysis,
less attention has been paid to the possible involvement
of defective bone formation[14]. As we know, normally,
the balance between bone resorption and formation leads
to the bone homeostasis[15,16]. It is therefore also critical
to consider the effect of wear debris on osteoblasts (OBs),
the cell type responsible for bone formation. Interestingly,
it has been demonstrated that following the phagocytosis
of polymethylmethacrylate (PMMA) by macrophages,
OBs are necessary to stimulate osteoclast generation and
migration in the peri-implant tissue [17-19]. These prior
studies shed some light on the importance of the OBs
response to mediators released by macrophages in AL;
unfortunately, they do not take into account the potential
effects of mediators released by osteoblasts upon macro-
phages.
Lipoxins (LXs) are endogenous eicosanoids that were syn-
thesized locally from arachidonate acid at sites of inflam-
mation and mediate pro-resolving activity [20]. LXA4,
LXB4 and their enantiomers are the major LXs in mam-
mals so far reported[21]. A number of studies have dem-
onstrated the effect of LXA4 to counteract inflammation in
different cell and animal models, such as asthma, perio-
dontal disease, atherosclerosis, cystic fibrosis, gastrointes-
tinal disease, acute lung injury and rheumatic
diseases[20,22-28]. They are considered as endogenous
"stop signals" for inflammation, but till now, no relative
report about the role of LXs in progress or prevention of
AL.
Thus in this study, we applied the co-culture system to test
the crosstalk between macrophage and OB and the poten-
tial therapeutic effect of LXs on these cells. The present
study was an initial research to examine the inhibitory
effect of LXs on AL.
Methods
Preparation of PMMA particles and LXA4
Spherical PMMA particles (Polysciences, USA), with mean
diameter 6.0 ± 1.8 μm, were measured by a Coulter Mult-
isizer II (Coulter Electronics) and it was confirmed that
ninety percent of the particles were <10 μm in diameter.
The particles were rinsed in 70% ethanol for three times
and sterilized in 70% ethanol for 48 h, then washed three
times in sterile phosphate buffered saline (PBS). A Limu-
lus Amebocyte Lysate kit (BioWhittaker, USA) was used to
test negative for endotoxin. After that, the particles were
then suspended in sterile PBS at 5 mg/ml (1 × 108 parti-
cles/ml) till use.
LXA4 (Cayman Chemical Company, USA) was stored at -
80°C until being diluted in serum-free culture medium
immediately before use.
Cell Culture and Preparation of Conditioned Medium
The RAW264.7 murine macrophage cell line (The Cell
Bank of Type Culture Collection of Chinese Academy of
Sciences, China) was cultured as we did before[29]. Cells
were cultured at 37°C in RPMI-1640 (Gibco BLR Life
Technologies Inc, USA) containing 10% heat-inactivated
fetal calf serum (FCS) (Sigma Chemical Co, USA), 2 g/L
NaHCO3 (pH = 7.4), penicillin (100 units/ml) and strep-
tomycin sulfate (100 μg/ml) in a humidified atmosphere
of 5% CO2.
The MC3T3-E1 murine OB cell line (China Center for
Type Culture Collection) was used in this study because it
bore many similarities to OB, such as morphology, pro-
duction of calcified bone matrix, collagen, and alkaline
phosphatase [30]. These cells were maintained in DMEM
(Gibco BRL, USA) with 10% FCS, OPI Media Supplement
(1 mM oxaloacetate, 0.45 mM pyruvate, 0.2 U/ml insulin,
Sigma, USA) and antibiotics. Cells were kept in an incuba-
tor as described above.
Co-culture model was established as the following[30].
Macrophages were seeded in Falcon 6-well plates (BD Bio-
science, USA) at a density of 2 × 106 cells per well with 3
ml of medium. Simultaneously, OBs were seeded onto 6-
well culture dish inserts (BD Bioscience, USA) at a density
of 3 × 105 cells per insert with 2 ml of media. The insertBMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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contained a membrane at the bottom onto which cells
could grow but was semi-permeable to soluble factors.
Macrophages and OBs were incubated separately for 24
hours then rinsed twice with sterile PBS. After that, PMMA
particles in DMEM/10% FCS were added to the macro-
phages. Fresh medium was added to the OBs. The inserts
with the OBs were then placed into the culture dishes
which contained the macrophages and particles. The co-
cultured cells were incubated for additional 24 or 48
hours.
ELISA
The conditioned medium were collected, filtered through
a 0.22 mm filter, and then assayed for some inflamma-
tion-related cytokines. LXA4 concentration in cell superna-
tants was determined using ELISA kit (Oxford Biomedical
Research, USA). TNF-α, IL-1β, PGE2 and GM-CSF were
determined using ELISA kit (Pierce, USA). All above tests
were accomplished according to the manufacturer's
instructions.
Gene Silencing
Based on the previous report[31], a siRNA against mice
15-lipoxygenase (15-LO) was chemically synthesized and
purified (GeneChem, Inc., Shanghai, China). The
sequences of the siRNA oligos used were following: 15LO-
siRNA-233: sense 5'-GCA ACU GGA UUU CUG UGA
AGG-3', antisense 3'-CGU UGA CCU AAA GAC ACU
UCC-5'; 15LO-siRNA-826: sense 5'-GAA GCG GAU UUC
UUC CUU CUG-3', antisense 3'-CUU CGC CUA AAG
AAG GAA GAC-5'; Scramble siRNA: sense 5'-GAU GCG
GAA UUG UUC CUA CUG-3', antisense 3'-CUA CGC
CUU AAC AAG GAU GAC-5'. The mix of 15LO-siRNA-
233 and 15LO-siRNA-826 or negative control of scramble
siRNA in serum-free medium was transfected into RAW
264.7 macrophages using Lipofectamine 2000 (Invitro-
gen, USA). 4 hours after then, medium was changed to
complete medium and cells were allowed to recover for
additional 24 hours prior to co-cultured with OBs or 15-
LO mRNA measuring, or 48 hours prior to 15-LO protein
measuring.
Real time quantitative reverse transcriptase-polymerase 
chain reaction (RT-QPCR)
Total cellular RNA was isolated from cultured cells using
RNeasy mini kit (Qiagen Inc., USA). First strand cDNA
was reverse transcribed from 2.0 μg of total RNA using a
high capacity cDNA archive kit (Applied Biosystems,
USA). MRNA level of 15-LO was quantified with specific
primers: sense 5'-ACC CCA CCG CCG ATT TT-3', anti-
sense 5'-AGC TTC GGA CCC AGC ATT T-3'. GAPDH was
applied as internal control with specific primers: sense 5'-
TGT GTC CGT CGT GGA TCT GA-3', antisense 5'-CCT
GCT TCA CCA CCT TCT TGA T-3'[32,33]. CDNA (90 ng)
was mixed with ABI TaqMan Universal PCR Master Mix
and the appropriate ABI TaqMan Gene Expression Assay
for the gene of interest. We used the comparative cycle
threshold (CT) method (2-ΔΔCT) to calculate relative gene
expression under experimental and control conditions
normalized to GAPDH. The results were expressed as fold-
change over control values[34].
Calvarial bone resorption assay
Bone resorption was quantified by measuring calcium
release from 5-day-old mice calvaria in vitro[35]. Briefly,
halved calvaria were cultured singly on stainless steel grids
in 30-mm dishes with 1.5 ml BGJb medium (Sigma
Chemical Co, USA) supplemented with 5% complement-
inactivated FCS, 1% penicillin/streptomycin and 50 mg/
ml ascorbic acid (Sigma Chemical Co, USA). The plates
were then incubated for 24 hours at 37°C with 5% CO2.
Then the media were aspirated and the wells and disks
were rinsed twice with sterile PBS. A 1:1 mixture of differ-
ent conditioned medium to BGJb/FCS/Antibiotic, and a
1:1 mixture of DMEM/FCS with BGJb/FCS/Antibiotic
were placed in control plates. The calvaria were cultured
for a further 48 hours and then the calcium content of the
media were measured by automated colorimetric assay. In
all assays, part of calvaria remained unstimulated to pro-
vide a measure of spontaneous calcium release from
bone, and part of calvaria were cultured in the presence of
1 mM PGE2 to demonstrate that the bone explants were
metabolically responsive.
Western immunoblotting
Cell lysates were prepared in RIPA buffer supplemented
with a full spectrum protease inhibitor cocktail (Roche
Biochemicals, USA), and then subjected to SDS-PAGE
electrophoresis and subsequent membrane transfer.
Before probing with Abs, the blotted membranes were
blocked with 3% (w/v) BSA in 1% TBS-Tween 20 for 1 h.
Mice anti-15-LO antibodies (Cell Signaling Technologies,
USA) were used for membrane immunostaining. After
washing 3 times with TBS-Tween 20 at room temperature,
the membranes were incubated for 1 h with a HRP-conju-
gated secondary Ab. Membranes were washed three times
in TBS-Tween 20 and developed with ECL reagent (Milli-
pore). Appropriate dilutions of antibody were empirically
derived.
All above studies were approved by the Ethical Committee
of Tongji Medical College, Huazhong University of Sci-
ence and Technology, China.
Statistical analysis of the data
Statistical analysis among groups was performed by one-
way ANOVA test. Data were expressed as mean ± standard
error of the mean. A P-value of less than 0.05 was consid-
ered as significant difference.BMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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Results
LXA4 inhibited the pro-inflammatory cytokines induced by 
PMMA
PMMA particles were widely used in TJR and generally
found in peri-prosthetic tissue. Thus in our study, they
served as stimulator to trigger the inflammation of macro-
phages. Different concentration of PMMA (final concen-
tration: 0.1 mg/ml, 0.5 mg/ml and 1.0 mg/ml) were
added into RAW 264.7 culture medium 12, 24 or 48 hours
prior to test. It was confirmed that (Fig. 1), in all of the
PMMA concentration groups, the pro-inflammatory
cytokines were increased in a time-dependent manner in
12 hours to 48 hours after treatment (P < 0.001 compared
to control groups). The effect of PMMA at a concentration
higher than 1 mg/ml was also studied. It was confirmed
that 1 mg/ml PMMA did not reach the highest plateau
(data not shown).
Then, in order to study the effect of LXA4, 1.0 mg/ml
PMMA was applied to stimulate the macrophages, while,
0–100 nM LXA4 was administrated simultaneously. After
24 hours, as seen in Fig. 2, LXA4 showed inhibitory effect
on 1.0 mg/ml PMMA-induced pro-inflammatory
cytokines production in a dose-dependent manner. Com-
pared with the cells without LXA4 treatment, TNF-α, PGE2
and GM-CSF in 50 nM LXA4 treated cells and TNF-α, IL-
1β, PGE2 and GM-CSF in 100 nM LXA4 treated cells were
significantly lower (P < 0.05).
LXA4 blocked the bone resorption induced by PMMA
Since the resorptive activity of culture media from macro-
phages exposed to diverse types of particles had been doc-
umented[36], we further studied the effect of LXA4 on in
vitro calvarial bone resorption. The culture media from
control cells, PMMA stimulated cells or both PMMA and
LXA4 treated cells were added into calvarial bone tissue,
respectively. It was shown in Fig. 3, after 48 hours treat-
ment, ionized calcium level was obviously increased from
0.91 ± 0.05 mM in control groups to 3.22 ± 0.42 mM in
1.0 mg/ml PMMA stimulated groups (P < 0.01), while,
LXA4 in all concentrations decreased the calcium enhance.
Statistical difference could be seen in 100 nM LXA4 treated
group.
Effect of PMMA on endogenous LXA4 production
Above data showed an important anti-inflammatory role
of exogenous LXA4 on the PMMA induced inflammation
in cultured macrophages. To determine whether endog-
enous LXA4 formation also played a role in the resolution
of peri-implant inflammation induced by wear debris, we
next determined weather PMMA could change the pro-
duction of LXA4 in RAW 264.7 cells. RAW 264.7 macro-
Changes of pro-inflammatory cytokines in culture media of macrophages exposed to different concentration of PMMA Figure 1
Changes of pro-inflammatory cytokines in culture media of macrophages exposed to different concentration 
of PMMA. All the cytokines were measured with correspondent ELISA kits. **, P < 0.001 compared to 0 hour group.BMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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LXA4 inhibited the production of pro-inflammatory cytokines in culture media of macrophages stimulated with PMMA Figure 2
LXA4 inhibited the production of pro-inflammatory cytokines in culture media of macrophages stimulated 
with PMMA. Cells were treated with 1.0 mg/ml PMMA and different dose of LXA4 for 24 hours. **, P < 0.001 compared to 
control group; #, P < 0.05 compared to cells treated with PMMA only.
LXA4 blocked PMMA stimulated calvarial bone resorption Figure 3
LXA4 blocked PMMA stimulated calvarial bone resorption. Each point represented the mean ± standard error of 
mean of 5-calvarial halves. **, P < 0.001 compared to control group; #, P < 0.05 compared to cells treated with PMMA only.BMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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phages were cultured alone or co-cultured with MC3T3-
E1 OB cell line and treated with 1.0 mg/ml PMMA for 48
hours. It was found that, in supernatant from macro-
phages cultured alone, LXA4 could be detected in neither
control cells nor cells treated with PMMA (Fig. 4.). In
supernatant from co-cultured cells exposed to PMMA,
LXA4  was increased significantly, while, this enhance
could be partly inhibited by 15-LO siRNA, which could
block the expression of 15-LO, a key enzyme to LXs pro-
duction in macrophages[31]. The block of 15-LO expres-
sion by 15-LO siRNA in macrophages were confirmed by
RT-QPCR and western blotting (Fig. 4B and 4C).
Effect of endogenous LXA4 on PMMA induced 
inflammation in macrophages
Now that we found LXA4 could be generated in macro-
phages exposed to both OB and PMMA, we further tested
the effect of endogenous LXA4 on PMMA induced inflam-
mation. Macrophages were co-cultured with OB and
treated with 1.0 mg/ml PMMA with or without 15-LO
siRNA 24 hours prior to culture media being collected. As
seen in Fig. 5, except PGE2, all other pro-inflammatory
cytokines studied were obviously higher when 15-LO was
blocked.
Effect of endogenous LXA4 on PMMA induced bone 
resorption
Because increase of pro-inflammatory cytokines paral-
leled bone resorption in both AL patients and our above
results[30], we next examined the contribution of endog-
enous LXA4 to PMMA induced bone resorption. The data
showed that 15-LO siRNA significantly accelerated the
bone resorption (Fig. 6, P < 0.05). Very interesting, we
also found that after PMMA stimulation, media from co-
Effect of PMMA on endogenous LXA4 production Figure 4
Effect of PMMA on endogenous LXA4 production. A, LXA4 content in culture media was monitored with ELISA kit. **, P 
< 0.01 compared to macrophages+PMMA; #, P < 0.05 compared with macrophage+OB+PMMA. B, Inhibition of 15-LO siRNA 
on 15-LO mRNA expression measured by RT-QPCR. Results were normalized to GAPDH and expressed as fold induction 
over cells co-cultured with OB without 15-LO siRNA. C, Inhibition of 15-LO siRNA on 15-LO protein expression measured 
by western blotting. GAPDH was applied as internal control.BMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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cultured cells lead to obviously higher calcium content
than media from macrophages cultured alone (Fig. 6, P <
0.05).
Discussion
Substantial progress has been made in recent years eluci-
dating the mechanisms responsible for AL. One area has
expanded rapidly is the demonstration that pro-inflam-
matory cytokines are not only produced in response to
wear particles but also responsible for the downstream
processes leading to osteolysis [37,38]. Undoubtedly,
anti-inflammation is a good therapeutic option deserving
attention. Some of the anti-inflammatory agents have
yielded encouraging results in animal models of AL. For
example, Etanercept[39] and pentoxifylline[40], a decoy
receptor for TNF and an inhibitor of TNF secretion,
respectively, have been independently shown to attenuate
particle-induced osteolysis in the murine calvarial model,
along with COX2 inhibitor Celecoxib[41].
However, despite these encouraging animal studies sug-
gesting an association between AL and pro-inflammatory
cytokines, no approved treatments are proved to perform
in the prevention or treatment of human osteolysis[14].
Orally administration of pentoxifylline can reduce wear
debris induced inflammation in isolated monocytes from
healthy subjects[42]. But we do not know weather it could
also work in patients with AL. A small clinical trial about
Etanercept in osteolysis patients proved inconclusive[43].
Although it is found that systemic trafficking of macro-
phages to peri-implant tissue could be induced by bone
cement particles in mice[12], there is no clear evidence in
favor of systemic elevated levels of pro-inflammatory
markers in serum of patients[14,44-46]. Meanwhile, even
if multiple pro-inflammatory cytokines, such as IL-1, IL-6
and TNF-α, are crucial to osteolysis and ultimately AL, the
synergistic interactions among these cytokines are
required. Knocking out of any one of these cytokines or
their receptors dose not completely protect murine cal-
varia from particle-induced osteolysis[38]. For example,
in the murine femoral model, knock out of the IL-1 recep-
tor blocked particle-induced inflammation but not osteol-
ysis[47]. Similarly, neutralizing antibodies to IL-1 did not
block osteolysis in an organ culture model of aseptic loos-
ening[48]. Even in the experiments in double knock out
mice lacking both IL-1 receptor and IL-6 or both TNF
receptor-1 and TNF receptor-2 osteolysis also was not sub-
stantially altered[38].
Effect of endogenous LXA4 on the production of pro-inflammatory cytokines Figure 5
Effect of endogenous LXA4 on the production of pro-inflammatory cytokines. Culture media were collected 24 
hours after treatment. **, P < 0.01 compared to control Mφ cells; #, P < 0.05 compared to Mφ+OB+PMMA cells.BMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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Current unsatisfactory situation of AL prevention and
treatment urges us to go back and ask help from the
progress in study on mechanism of inflammation itself.
As we know, a well-integrated host inflammatory
response is essential in maintaining health and fighting
disease[49]. Acute inflammation has several outcomes
that include progression to chronic inflammation, scar-
ring and fibrosis or complete resolution[50]. Resolution
by precise definition and characterization is not the same
as endogenous anti-inflammation. It is defined as a highly
coordinated and process involving changes from gene
transcription to local mediators generation within the res-
olution phase, not just in vivo dwindling with time of
chemotaxic stimuli at the site of inflammation [50-52].
Importantly, successful resolution will limit excessive tis-
sue injury and give little opportunity for the development
of chronic, immune-mediated inflammation, like in
AL[53].
Based upon previous understanding on inflammation,
many drugs try to tame inflammation by inhibiting what
occurring at the beginning of the immune response, such
as blocking TNF-α or IL-1[38]. However, rather than nip
an inflammation in the bud – which may thwart the
body's own attempt to heal – a better approach may be to
enhance the activity of these natural resolution-promot-
ing compounds. Hence, resolution-directed therapeutics
have become a new but attractive terrain for drug design
in inflammation related diseases[53,54]. As important
lipid pro-resolution mediators, LXs are found to accelerate
resolution in different cell and animal models, such as
asthma, periodontal disease, atherosclerosis, cystic fibro-
sis, gastrointestinal disease, acute lung injury and rheu-
matic diseases[20,22-28]. But till now, no similar study
on AL was reported.
Then, after it was confirmed that, in our cell model,
PMMA showed a time-dependent manner to trigger pro-
duction of all the pro-inflammatory cytokines studied, we
administrated exogenous LXA4 to make sure if it could
inhibit PMMA induced inflammation in cultured macro-
phages. As shown in the results part, LXA4 presented an
inhibitory effect on both generation of above cytokines
and PMMA stimulated calvarial bone resorption with a
dose-dependent manner.
Since LXs are important endogenous lipids generated by
5- and 15-LO[55,56], we explore further the role of
PMMA on LXA4 production in macrophages. It was found
that LXA4 in culture media from neither rest macrophages
nor macrophages cultured alone exposing to PMMA was
detectable. Macrophages could only secrete LXA4  after
exposed to PMMA when they were co-cultured with OBs.
This might because LXs are transcellular metabolism of
AA by LO/LO interaction pathways in different cells[53].
Next, we also found that when LXA4  generation was
blocked with 15-LO siRNA, which could down-regulate
both mRNA and protein expression in macrophages as
Effect of endogenous LXA4 on PMMA induced bone resorption Figure 6
Effect of endogenous LXA4 on PMMA induced bone resorption. **, P < 0.01 compared to Mφ group; #, P < 0.05 com-
pared to Mφ+OB+PMMA group; ##, P < 0.05 compared to Mφ+PMMA group.BMC Musculoskeletal Disorders 2009, 10:57 http://www.biomedcentral.com/1471-2474/10/57
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shown in Fig. 4, the PMMA induced inflammation
became more serious. The changes included elevated pro-
inflammatory cytokines and accelerated bone resorption.
It is clear that exogenous LXA4 at the concentration of 1 to
10 nM did not show any obvious influence on PMMA-
induced cytokine production or bone resorption (Fig. 2
and 3), while, the concentration of LXA4 produced by co-
culture system exposed to PMMA was just 2.5 ± 0.8 nM
(Fig. 4). This concentration difference may be because
that LXA4 is a short-acting lipid, both in vitro and in
vivo[57]. Exogenous LXA4 could be rapidly converted by
initial dehydrogenation at carbon 15 to 15-oxo-LXA4
which is biologically inactive [58], but endogenous LXA4
was produced persistently.
We also found another interesting phenomena that when
macrophage were co-cultured with OBs, after PMMA chal-
lenge, both pro-inflammatory cytokines and bone resorp-
tion level are higher than which are in macrophages
alone. Combining with what we concluded above that the
cooperation of OBs to macrophages was also necessary to
generation and effect of LXA4, it indicated that the micro-
circumstance in the peri-implant tissue contribute not
only to the beginning of particles-induced inflammation
but also the resolution after that. The balance between
these two parts decides the patients' destiny after TJR. It
also showed that peri-implant inflammation could be bet-
ter reproduced by this co-culture model.
Finally, it should be pointed out that in this paper we just
used PMMA particles to mimic the inflammation in mac-
rophages and OBs which participate in periprosthetic
inflammation of AL patients. A related limitation is that it
could not present all the changes in patients who use pros-
thesis made of other materials. Some other products of
15-LO, like 15-HETE and hepoxilins[59], may also con-
tribute to the PMMA-induced inflammation in the co-cul-
ture system we used here. The underlying mechanisms
may vary in different prosthesis components, even in dif-
ferent size and dose of same particles[30,60]. And, differ-
ences between the in vivo and the cell culture study
methods make it still too early to conclude whether LXs
contribute to prevention or treatment of AL.
Conclusion
Taken together, our findings indicate that LXA4 has an
inhibitory effect on PMMA-induced inflammation in a
macrophage and OB co-culture system. Although it is now
hard to say that LXA4 could be used in the treatment of
patient suffered from AL, this study is a valuable attempt
in searching for alternative therapeutic strategy involving
endogenous anti-inflammatory and pro-resolving lipid
mediators.
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